-
Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap
Tuesday, April 27, 2021 - 7:40am | 313Read More...Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in patients with allergic conjunctivitis. The 95-subject trial achieved statistical significance for the primary endpoint and...
-
Aldeyra Therapeutics Surges 38%: Here's Why
Monday, February 29, 2016 - 12:11pm | 236Read More...Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a nano-cap biotechnology company, surged higher by more than 38 percent Monday morning after the company reported positive results from a Phase IIa clinical trial. Aldeyra Therapeutics reported that the results from a randomized, parallel-group...
